0001104659-20-122717.txt : 20201109 0001104659-20-122717.hdr.sgml : 20201109 20201109063009 ACCESSION NUMBER: 0001104659-20-122717 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20201109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201109 DATE AS OF CHANGE: 20201109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mersana Therapeutics, Inc. CENTRAL INDEX KEY: 0001442836 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38129 FILM NUMBER: 201296015 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-498-0020 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC DATE OF NAME CHANGE: 20080813 8-K 1 tm2035341d1_8k.htm FORM 8-K
0001442836 false 0001442836 2020-11-09 2020-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 9, 2020

 

MERSANA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware     001-38129     04-3562403  
(State or other jurisdiction of
incorporation)  
  (Commission File Number)     (IRS Employer
Identification No.)  

 

840 Memorial Drive
Cambridge, MA 02139
   
Cambridge, MA     02139  
(Address of principal executive offices)     (Zip Code)  

 

(Registrant’s telephone number, including area code): (617) 498-0020

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, $0.0001 par value MRSN The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 2.02Results of Operations and Financial Condition.

 

On November 9, 2020, Mersana Therapeutics, Inc., issued a press release announcing its financial results for the second quarter ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release by Mersana Therapeutics, Inc., on November 9, 2020
104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MERSANA THERAPEUTICS, INC.
     
  By:  /s/ Brian DeSchuytner
    Brian DeSchuytner
Senior Vice President, Finance & Product Strategy

 

Date: November 9, 2020

 

 

 

EX-99.1 2 tm2035341d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Mersana Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

 

-      Presented additional data from XMT-1536 Phase 1 study at ESMO demonstrating

compelling and consistent activity and tolerability profile in ovarian cancer

 

-      Received FDA Fast Track Designation for XMT-1536 for patients with heavily-pretreated

ovarian cancer

 

-      Ended Q3 2020 with $271 million in cash

 

CAMBRIDGE, Mass., November 9, 2020 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and provided a business update for the third quarter ended September 30, 2020.

 

“During the quarter, we presented an update from the ovarian cancer cohort of the XMT-1536 Phase 1 study at ESMO, which showed continued significant anti-tumor activity in very late-stage ovarian cancer patients with response rates far exceeding standard of care and a differentiated tolerability profile. We are very encouraged by the potential of this promising therapy for people with ovarian cancer, and we look forward to providing an additional update on this program at an Analyst and Investor day around year-end,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. “We’ve also made great progress in advancing a deep pipeline of therapies derived from our multiple innovative ADC platforms. XMT-1592, a Dolasynthen ADC targeting NaPi2b, is actively enrolling patients in a Phase 1 dose escalation study. We’ve continued to advance our B7-H4 and first Immunosynthen STING-agonist ADC development candidates and look forward to sharing the data sets supporting the clinical development of these promising molecules.”

 

Recent Highlights and Updates

 

Clinical Programs

 

·Reported positive incremental interim data from the ovarian cancer cohort of the XMT-1536 Phase 1 expansion study at the European Society of Medical Oncology (ESMO) Virtual Congress. These data showed a safety profile consistent with previously reported expansion data without severe neutropenia, peripheral neuropathy, or ocular toxicities; continued promising antitumor activity in ovarian cancer with 2/29 (7%) who achieved confirmed complete responses (CRs) and 8/29 (28%) who achieved confirmed partial responses (PRs) for an objective response rate (ORR) of 34%; and continued support for a NaPi2b biomarker-based patient selection strategy based on depth, time on study and quality of response. The Company has exceeded its recruitment goal of 40-45 patients in the ovarian cancer cohort of the XMT-1536 Phase 1 expansion study and will continue to enroll patients throughout the remainder of 2020.

 

 

 

·XMT-1536 granted Fast Track Designation underscoring the high unmet medical need in ovarian cancer. In August 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for XMT-1536 for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy regardless of platinum status.

 

·Mersana plans to host a virtual Analyst and Investor Day event to provide an update on the ovarian cancer cohort of the XMT-1536 Phase 1 expansion study and the path forward in ovarian cancer around year end. The Company anticipates that the year-end disclosure will include efficacy data from approximately 40-45 RECIST evaluable patients, safety data from approximately 65-70 patients, and approximately three months of patient follow up since the last data cutoff date of August 18, 2020. In addition, the Company will review its plans for the registration-enabling study and outline its lifecycle management strategy for XMT-1536.

 

·New international sites added to support enrollment of the NSCLC adenocarcinoma patient cohort of the XMT-1536 Phase 1 expansion study. In the third quarter of 2020 the Company saw an increase in enrollment in the lung cancer cohort in parallel with the recent opening of international sites that had been delayed because of COVID-19. The Company will continue to recruit the expansion cohort and expects to discuss its data disclosure plans for the NSCLC adenocarcinoma patient cohort in early January 2021.

 

·Phase 1 dose escalation study of XMT-1592, a Dolasynthen ADC targeting NaPi2b, proceeding to higher dose levels. XMT-1592 is the Company’s first clinical candidate created using its new Dolasynthen ADC platform. In preclinical studies, XMT-1592 showed four times greater efficacy in a patient-derived lung tumor model in comparison to XMT-1536, the Company’s Dolaflexin ADC that has already shown success when targeted to NaPi2b in the clinic. The Company continues to dose escalate and expects to discuss its data disclosure plans for XMT-1592 in early January 2021.

 

Discovery & Platform Progress

 

·Mersana to present preclinical data supporting its first Immunosynthen development candidate in November 2020. Immunosynthen, the Company’s novel STING-agonist ADC platform, has generated preclinical data across multiple targets and models showing complete regression of tumors in vivo after a single, well-tolerated dose, consistent with increased cytokine expression and immune cell infiltration within the tumor, and immune memory. The Company plans to present additional preclinical mechanistic data supporting the targeted dual activation of the STING pathway in tumor cells and tumor-resident immune cells at the Society for Immunotherapy of Cancer (SITC) virtual meeting in November. In addition, the Company will host a webinar on November 16, 2020 where it plans to review the therapeutic rationale for the development of STING-agonist ADCs including preclinical mechanistic data showing STING activation in both tumor cells and tumor-resident immune cells, the development and optimization of the Immunosynthen platform, and preclinical data supporting the Company’s Immunosynthen ADC pipeline as well as the Investigational New Drug timeline for the Company’s first development candidate.

 

 

 

 

·Mersana on track disclose its first-in-class ADC targeting B7-H4 development candidate and supporting data around year end. B7-H4 is expressed on both tumor cells and immunosuppressive tumor-associated macrophages (TAMs). This provides the potential for both a direct, cytotoxic antitumor effect as well as for additional payload delivery to the tumor microenvironment that can further contribute to immunogenic cell death, dendritic cell activation, and stimulation of an immune response consistent with the features of the Company’s unique DolaLock payload. IND-enabling studies are ongoing, and the Company plans to disclose its development candidate and supporting data at a virtual Analyst and Investor Day around year end.

 

Corporate

 

·New addition to Executive Management Team. In August 2020, the Company announced the appointment of Chuck Miller as Senior Vice President of Regulatory Affairs. Mr. Miller was most recently Vice President of Regulatory Strategy and Labeling at TESARO, Inc before its acquisition by GSK. Prior to that, he worked as Executive Director of Regulatory Affairs at Cubist, before its acquisition by Merck.

 

·Refinancing of SVB Debt Agreement. In August 2020, the Company entered into a second amendment of its debt agreement with Silicon Valley Bank. The amendment provides for an increased commitment amount and an extension of the interest-only payment period into 2022. The Company is no longer required to maintain a minimum liquidity ratio.

 

Upcoming Events

 

·Mersana will give a corporate presentation at the 29th Annual Credit Suisse Virtual Healthcare Conference scheduled for Thursday, November 11, 2020 at 11:00 a.m. ET.

 

·Mersana will present preclinical data from its novel Immunosynthen STING-agonist ADC platform at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) as an on-demand poster display available from November 11 – 14, 2020.

 

·Mersana will host an Immunosynthen STING-Agonist ADC Platform webinar on Monday, November 16, 2020 at 8:00 a.m. ET.

 

Third Quarter 2020 Financial Results

 

Cash and cash equivalents as of September 30, 2020, were $270.9 million, compared to $99.8 million in cash, cash equivalents and marketable securities as of December 31, 2019. Net cash used in operating activities in the third quarter of 2020 was $20.2 million.

 

 

 

The Company expects that its cash and cash equivalents will enable it to fund its current operating plan commitments for more than two years. In addition, the Company has the option to draw additional funds through the debt financing agreement with Silicon Valley Bank.

 

·Collaboration revenue for the third quarter of 2020 was immaterial, compared to $0.8 million for the same period in 2019. The decrease in collaboration revenue was primarily a result of the completion of research services associated with a target included in the Merck KGaA agreement in the third quarter of 2019.

 

·Research and development expenses for the third quarter of 2020 were approximately $16.5 million, compared to $13.7 million for the same period in 2019. The difference was primarily due to an increase in manufacturing activities for XMT-1536 and our discovery stage programs, an increase in XMT-1536 and XMT-1592 clinical expenses, increased headcount and an increased valuation of stock-based awards, an increase in consulting and professional fees and advancement of companion diagnostics development efforts for the NaPi2b biomarker. The increase was partially offset by a decrease in preclinical development and manufacturing expenses for XMT-1592 and discontinuation of XMT-1522.

 

·General and administrative expenses for the third quarter of 2020 were approximately $5.9 million, compared to $4.4 million during the same period in 2019 primarily due to an increase in consulting and professional fees, an increase in valuation of stock-based awards, and an increase in facility-related costs as a result of the extension of the Company’s lease in March 2020.

 

·Net loss for the third quarter of 2020 was $22.5 million, or $0.33 per share, compared to a net loss of $16.8 million, or $0.35 per share, for the same period in 2019. Weighted average common shares outstanding for the quarters ended September 30, 2020 and September 30, 2019, were 68,419,192 and 47,833,607, respectively.

 

Conference Call Details

 

Mersana Therapeutics will host a conference call and webcast today at 8:00 a.m. ET to report financial results for the third quarter of 2020 and provide certain business updates. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7953159. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.

 

About Mersana Therapeutics

 

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

 

 

 

Forward-Looking Statements

 

This press release contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company’s business strategy and the design, progression and timing of its clinical trials. Forward-looking statements generally can be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continues,” “could,” “estimates,” “expects,” “goal,” “intends,” “may,” “on track,” “plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. The Company’s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company’s results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials, that the development and testing of the Company’s product candidates and new platforms will take longer and/or cost more than planned, and that the identification of new product candidates will take longer than planned, as well as those listed in the Company’s Annual Report on Form 10-K filed on February 28, 2020, with the Securities and Exchange Commission (“SEC”), the Company’s Quarterly Report on Form 10-Q filed on May 8, 2020, with the SEC and subsequent SEC filings. In addition, while we expect that the COVID-19 pandemic might adversely affect the Company’s preclinical and clinical development efforts, business operations and financial results, the extent of the impact on the Company’s operations and the value of and market for the Company’s common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

 

 

 

Mersana Therapeutics, Inc.

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

 

  

September 30,

2020

  

December 31,

2019

 
Cash, cash equivalents and marketable securities  $270,936   $99,790 
Working capital (1)   253,864    77,256 
Total assets   290,128    107,541 
Total stockholders' equity   253,308    78,318 

 

(1) The Company defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial statements for further detail regarding its current assets and current liabilities.

 

 

 

Mersana Therapeutics, Inc.

Condensed Consolidated Statement of Operations

(in thousands, except share and per share data)

(unaudited)

 

   Three months ended   Nine months ended 
   September 30,   September 30,   September 30,   September 30, 
   2020   2019   2020   2019 
Collaboration revenue  $11   $844   $817   $42,081 
Operating expenses:                    
Research and development   16,546    13,701    44,179    42,610 
General and administrative   5,881    4,436    15,988    13,072 
Total operating expenses   22,427    18,137    60,167    55,682 
Other income (expense), net   (73)   501    147    1,639 
Net loss  $(22,489)  $(16,792)  $(59,203)  $(11,962)
Other comprehensive income (loss):                    
Unrealized gain (loss) on marketable securities   (2)   17    (25)   36 
Comprehensive loss  $(22,491)  $(16,775)  $(59,228)  $(11,926)
Net loss per share attributable to common stockholders — basic and diluted  $(22,489)  $(16,792)  $(59,203)  $(11,962)
Net loss per share attributable to common stockholders — basic and diluted  $(0.33)  $(0.35)  $(1.00)  $(0.28)
Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted   68,419,192    47,833,607    59,086,202    42,011,340 

 

###

 

Contact:

 

Investor & Media Contact
Sarah Carmody, 617-844-8577

scarmody@mersana.com

 

 

EX-101.SCH 3 mrsn-20201109.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mrsn-20201109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mrsn-20201109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2035341d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001442836 2020-11-09 2020-11-09 iso4217:USD shares iso4217:USD shares 0001442836 false 8-K 2020-11-09 MERSANA THERAPEUTICS, INC. DE 001-38129 04-3562403 840 Memorial Drive Cambridge MA 02139 02139 617 498-0020 false false false false Common Stock, $0.0001 par value MRSN NASDAQ true true XML 7 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Nov. 09, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2020
Entity File Number 001-38129
Entity Registrant Name MERSANA THERAPEUTICS, INC.
Entity Central Index Key 0001442836
Entity Tax Identification Number 04-3562403
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 840 Memorial Drive
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 498-0020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol MRSN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mersana.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2035341d1_8k.htm mrsn-20201109.xsd mrsn-20201109_lab.xml mrsn-20201109_pre.xml tm2035341d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2035341d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2035341d1_8k.htm" ] }, "labelLink": { "local": [ "mrsn-20201109_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mrsn-20201109_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mrsn-20201109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mrsn", "nsuri": "http://mersana.com/20201109", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2035341d1_8k.htm", "contextRef": "From2020-11-09to2020-11-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://mersana.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2035341d1_8k.htm", "contextRef": "From2020-11-09to2020-11-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mersana.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-20-122717-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-122717-xbrl.zip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